Author

T. Ogata

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

K. Kato, J. Ajani, Y. Doki et al. · Annals of Oncology · 2 citations

Aug 2026

OA03-RF01.03. Non-Cisplatin-Based Preoperative Chemotherapy for Cisplatin-Unfit Esophageal Cancer: A Multicenter Retrospective Study in Japan

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Although cisplatin-based neoadjuvant chemotherapy is the standard for resectable esophageal squamous cell carcinoma in Japan, some patients are unfit due to age, renal, or cardiac dysfunction. No established treatment option exists for cisplatin-unfit...

Y. Ishizuka, Toru Kadono, Akitoshi Hakoda et al. · Diseases of the esophagus · 0 citations

Open access Aug 2026

OA03-RF01.04. Biomarkers and Questionnaires for Predicting the Development of Multiple Caners Within the Esophagus or Head and Neck After Endoscopic Resection

Long-term follow-up revealed a significant correlation between LVL grade, HRA-F/AUDIT scores, MCV/GGT levels, and the development of multiple SCC within the esophagus or head and neck, with the LVL grade emerging as the most powerful factor for risk stratification.

C. Katada, Tomonori Yano, T. Ogata et al. · Diseases of the esophagus · 0 citations